MedicaidCoverageLow impact
PT 83-26: Additional Authorized Treatment Center for CASGEVY for Cell and Gene Therapy Access Model for Sickle Cell Disease
Maryland Medicaid·MD · Hematology, Oncology·Managed Care
Effective date
Jan 26, 2026
We identified it
Jun 18, 2026
Summary
The University of Maryland Medical Center (UMMC) has been approved as an additional authorized treatment center to provide CASGEVY under Maryland's Cell and Gene Therapy Access Model for Sickle Cell Disease. Both UMMC and Children's National Medical Center can now administer CASGEVY and LYFGENIA under this model.
Action Required
No immediate action required for billing teams outside Maryland. This is informational regarding expanded treatment center availability for specialized cell and gene therapies for sickle cell disease patients in Maryland.